The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and IMMUNOPLANT.

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...

In non-low-risk DCIS of the breast, the addition of a TBB of radiation following postoperative WBI is associated with reduced local recurrence.

EPIK-B5 study evaluated alpelisib plus fulvestrant vs placebo for efficacy and safety in patients with PIK3CA-m HR+, HER2− advanced breast cancer who had progressed on a CDK4/6 inhibitor and an ...

Patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer can be safely treated without chemotherapy.

Less-invasive lymph node procedures are noninferior to axillary lymph node dissection for 3-year recurrence outcomes in breast cancer patients.

Researchers assessed survival outcomes for Asian patients with newly diagnosed AML vs White patients. Researchers determined Asian patients with newly diagnosed AML may have superior OS outcomes ...

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.